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Abstract
Background: Bell´s palsy is the most common cause of facial paralysis worldwide and the most common disorder of
the cranial nerves. It is a diagnosis of exclusion, accounting for 60–75% of all acquired peripheral facial nerve palsies.
Our case shows the first case of a microcystic adnexal carcinoma-like squamous cell carcinoma as a cause of facial
nerve palsy.
Case presentation: The patient, a 70-year-old Caucasian male, experienced subsequent functional impairment of the
trigeminal and the glossopharyngeal nerve about 1½ years after refractory facial nerve palsy.
An extensive clinical work-up and tissue biopsy of the surrounding parotid gland tissue was not able to determine the
cause of the paralysis. Primary infiltration of the facial nerve with subsequent spreading to the trigeminal and
glossopharyngeal nerve via neuroanastomoses was suspected. After discussing options with the patient, the main stem
of the facial nerve was resected to ascertain the diagnosis of MAC-like squamous cell carcinoma, and radiochemotherapy
was subsequently started.
Conclusion: This case report shows that even rare neoplastic etiologies should be considered as a cause of refractory
facial nerve palsy and that it is necessary to perform an extended diagnostic work-up to ascertain the diagnosis. This
includes high-resolution MRI imaging and, as perilesional parotid biopsies might be inadequate for rare cases like ours,
consideration of a direct nerve biopsy to establish the right diagnosis.
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Background
Facial nerve paralysis (FNP) involves the paralysis of any
structures innervated by the facial nerve, occurring either
in infranuclear/nuclear (“peripheral”) or supranuclear
(“central”) form. Individuals of all races and ages are af-
fected and can experience significant functional, social
and psychological consequences [1]. FNP is a frequent
problem, with an incidence of 17 to 35 cases per 100,000
individuals per year [1]. Other etiologies include viral or
bacterial infections, autoimmune diseases, malformations,
malignancies and traumas [2].
Bell´s palsy (BP; idiopathic facial nerve paralysis) is the
most common cause of facial paralysis worldwide and
the most common disorder of the cranial nerves [3].
With progressing age, 7–40 patients per year and per
100,000 individuals are affected by BP, with equal gender
distribution. BP is a diagnosis of exclusion, accounting
for 60–75% of all acquired peripheral FNPs [2].
The generally recommended work-up for new-onset
FNP consists of the clinical history, physical examination
and regular patient follow-up. Medical therapy with
corticosteroids should be started within the first 72 h after
the onset of symptoms in patients over the age of 16 with
all degrees of severity [3, 4]. This increases the rate of facial
nerve recovery [1] and significantly reduces the risk of syn-
kinesis [5]. In patients with severe to complete paresis, the
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combination of corticosteroids and antivirals can be used
[3, 4]. Electrostimulation, routine laboratory testing and
surgical decompression is not recommended in non refrac-
tory cases within the first 3 months [3, 4]. Eye protection,
e.g. wearing a moisture chamber at night, should be ap-
plied in every patient with incomplete eye closure, and in
severe cases an ophthalmologist should be consulted to
avoid cornea damage due to dry eyes [3, 4].
The prognosis for BP is good, with about 70% of the
cases resulting in spontaneous, complete recovery. In pa-
tients with incomplete paresis, the recovery rate is even
higher at 93–98%. Remission starts about 3–4 weeks after
onset. Symptoms normally resolve completely within 3–5
months [2, 4]. Although the prognosis for BP is good, not
every FNP resolves. Six months after the onset of symp-
toms at the latest, other differential diagnoses have to be
considered in refractory cases [2].
In the following, we describe a complex case of per-
sistent House-Brackmann VI FNP where the diagnosis
could only be made after excluding various differential
diagnoses.
Case presentation
A 70-year-old male first presented at the Department of
Otorhinolaryngology, Head and Neck Surgery, University
of Erlangen-Nürnberg, in 2014 with refractory facial par-
alysis (House Brackmann VI) that had affected the right
side for 2 months. No change in facial nerve function
could be seen after intravenous therapy with cortisone [6],
ceftriaxone and valacyclovir had been carried out exter-
nally for 10 days.
The previous medical history included canal wall down
tympanoplasty of the right ear in 1966 due to cholestea-
toma. Other symptoms, such as change in hearing, vertigo
or tinnitus, were negated.
Clinical examination showed normal otoscopic find-
ings after canal wall down tympanoplasty on the right
side. The audiogram showed a severe combined hearing
loss with a conductive component of 15 dB on the right
side (unchanged during the course), while the left side
was normal.
Laboratory examination was unremarkable, including
the serology for Lyme´s disease and varicella zoster virus.
An ultrasound scan of the parotid gland produced normal
findings as well. Metabolic disorders such as diabetes were
excluded and a routine ophthalmologic examination was
also normal.
The facial nerve electromyogram, performed 3 months
after the onset of symptoms, showed no signs of degen-
eration or reinnervation.
An MRI scan was performed, and recurrent cholestea-
toma on the right side was suggested. Additionally, the
facial nerve demonstrated contrast enhancement and thick-
ening proximal to the geniculate ganglion up to the
peripheral nerve endings; neuritis was assumed. No signs
of tumors of the cerebellopontine angle or other intracra-
nial tumors could be detected.
As the routine work-up did not show the cause of
the FNP, other differentials had to be considered. Due
to the suspicion of recurrent cholesteatoma, surgical ex-
ploration of the right mastoid was performed and a
small cholesteatoma was removed. Surprisingly, the
bony facial canal was intact and no contact with the fa-
cial nerve could be seen. It was concluded that this
finding could not be regarded as the cause of the FNP.
Facial nerve decompression was not performed due to
the long segment enhancement of the facial nerve.
Recommended follow-up appointments were not kept
for 1 year. At his next visit 1 year after onset of symp-
toms, the patient complained of a new onset of
hypesthesia on the right side of the face in the trigeminal
supply territory (V2 + 3).
As the patient had swallowing problems, the
renewed clinical examination showed an impaired gag
reflex. Contrast swallow showed an insufficiency of
the upper esophageal sphincter. Due to this finding
and the backdrop phenomenon, an affection of the
glossopharyngeal nerve was suspected. As transnasal
fiberoptic examination showed aspiration the patient
received no more oral nutrition from this point on,
and a percutaneous endoscopic gastrostomy tube was
placed.
Extensive neurological examinations (gross examination,
somatosensory-evoked potentials (SEPs), electroencephal-
ography (EEG), Doppler ultrasound, lumbar puncture,
autoimmune testing, plasmapheresis) were carried out to
exclude further differentials, but still no diagnosis could
be found.
MRI was repeated, demonstrating abnormal contrast en-
hancement of the facial and trigeminal nerve and a diffuse
contrast-enhancing lesion inside the right parotid gland
(Figs. 1 and 2). Explorative surgery of the parotid gland
was performed and multiple biopsies were taken from the
corresponding areas. Histologically, the biopsies showed
no signs of malignancy or inflammation.
After discussing options with the patient, the main
stem of the facial nerve was resected.
Histologically, the facial nerve was found to be infil-
trated by squamous cell carcinoma growing in minute
nests and cords very reminiscent of microcystic adnexal
carcinoma (MAC) of the skin, but with pure squamoid
differentiation (Fig. 3). A primary infiltration of the facial
nerve with subsequent spreading to the trigeminal and
glossopharyngeal nerve via neuroanastomoses was
suspected.
An 18-Fluoro-deoxyglucose-Positron-Emission-Tomog-
raphy/Computed Tomography (PET-CT) showed no new
focus, signs of metastases or any other primary tumor.
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As surgical treatment was not an option due to the
perineural growth of the tumor, radiochemotherapy was
recommended at our interdisciplinary tumor conference
and was realized (up to a total dose of 66.6 Gy); chemo-
therapy was also given with CDDP (Cisplatin)).
Discussion
Microcystic adnexal carcinoma (MAC) is a rare tumor
that was first described in 1982 [7]. It is a slow-growing,
locally aggressive, deeply infiltrating tumor that can ex-
tend into muscles, fat and bones [8]. Perineural or intra-
neural involvement is characteristic. Although it only
rarely metastasizes, the local recurrence rate is high [8].
MAC occurs mainly in the centrofacial skin. However,
rare examples have been described in the orbita, the ex-
ternal ear canal, the minor salivary glands, the vulva and
the axilla [7]. To date, only six cases have been reported
in non-cutaneous head and neck sites, including the
tongue (n = 3), and one case each in the nasopharynx,
floor of the mouth and parotid gland [9].
Histologically, it is characterized by an infiltrative pat-
tern of slightly atypical cells forming cords, nests and a
duct-like structure with a prominent desmoplastic stro-
mal reaction [8].
This is the first described case of MAC occurring at
the facial nerve (and equiprobably to the other caudal
cranial nerves affected) and is a new differential diagno-
sis for persistent FNP/ BP. Although no clear-cut pri-
mary tumor mass could be identified, it is likely that the
primary tumor originated within the parotid gland and
that the extensive neurotropic growth via nerve anasto-
moses might have precluded the formation of a larger
tumor mass.
Unlike central FNP, in peripheral idiopathic FNPs im-
aging is not crucial for work-up or treatment in patients
with typical clinical findings, as most patients recover
within 3–6 months of onset [10]. Imaging is, therefore,
only recommended to rule out neoplasms and other
causes in patients with no response to initial treatment
after 3 months or with progressive facial nerve paralysis
[3, 4]. Some authors suggest performing native and
contrast-enhanced imaging of the parotid gland, tem-
poral bone and brain if restoration has not occurred
within 3 months and a repeat of the imaging after
7 months if a definable cause still cannot be found. In
patients with local progression/ recurrence, a second
paralysis on the same side, paralysis of isolated branches
of the facial nerve or involvement of other cranial
nerves, contrast-enhanced imaging should be considered
immediately [1, 4, 10]. In our case, imaging was per-
formed within the first 3 months of onset of symptoms
to rule out recurrent cholesteatoma.
Close follow-up is important to pick up novel neurologic
or ocular findings or in the case of incomplete recovery
3 months after onset. Referrals to other specialties should
be performed accordingly [2].
If a thorough diagnostic work-up still does not lead to a
diagnosis, other means should be considered. Currently,
there are no guidelines concerning soft tissue or facial
nerve biopsies. Some authors do, however, suggest
Fig. 1 MR-RAGE after contrast (Gd), oblique sagittal: Course of the
facial nerve and thickened facial nerve entering the parotid gland
Fig. 2 T1 TSE FS after contrast, axial: thickened facial nerve
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considering a biopsy of the surrounding tissue of the facial
nerve, e.g. parotid gland tissue in the case of negative im-
aging at 7 months [1, 5]. In patients with non-resolving
FNP, an exploration, or even a biopsy of the facial nerve it-
self, can be discussed. Factors underlining the need for
exploration are pain or regional skin cancer and the in-
volvement of other cranial nerves [11]. In our case, facial
and trigeminal nerve biopsies were discussed to force a
diagnosis. Due to the long-persisting FNP, the disease pro-
gression and the age of the patient, we decided to biopsy
the main stem of the facial nerve.
In patients with contrast enhancement of the facial
nerve or the surrounding tissue on MRI, the surrounding
tissue/ the facial nerve should be biopsied closest to the
enhancement. However, it is crucial to know that contrast
enhancement of the facial nerve can be seen up to the
geniculate ganglion, even in non-diseased patients. The
tympanic and mastoid segments do not usually demon-
strate enhancement except in cases of neuritis, tumor or
palsy. Asymmetric enhancement between the ipsi- and
contralateral sides is highly suggestive, although not very
specific. Contrast enhancement beyond the stylomastoid
notch as well as thickening of the nerve should raise the
suspicion of inflammatory or neoplastic involvement.
An MRI scan can also be of prognostic value. Enhance-
ment limited to the geniculate ganglion, labyrinthine, and
proximal tympanic facial nerve more often showed a
complete return of facial function [12].
Conclusions
A neoplastic etiology should be considered as a cause of
FNP, particularly in cases where idiopathic FNP persists
longer than 3 months, and a thorough work up is war-
ranted in such cases. Work-up in FNP persisting over
3 months should include high-resolution MRI imaging
and, as perilesional biopsies might be inadequate for rare
cases like ours, consideration of a direct nerve biopsy to
establish the right diagnosis.
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Fig. 3 Histological sections. Top left: The biopsy of the facial nerve shows scanty, retiform-arranged infiltrates of the carcinoma within abundant
inflammatory fibrous tissue. Top right: High magnification of tumor infiltrates. Bottom left: The CK5 stain shows numerous unexpected tumor nests
with small strands and adenoid nests (MAC-like). Bottom right: KI67 shows an extremely high proliferation of the tumor cells
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